🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

12 results for “acalabrutinib” Clear

  1. ACALABRUTINIB , Nemtabrutinib, Nemtabrutinib, Nemtabrutinib, Nemtabrutinib, IBRUTINIB

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  2. CHLORAMBUCIL, FLUDARABINE PHOSPHATE, Lisaftoclax, ACALABRUTINIB, Lisaftoclax, Lisaftoclax, RITUXIMAB, CYCLOPHOSPHAMIDE MONOHYDRATE, RITUXIMAB

    Pharma Mar S.A.

    Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  3. Nemtabrutinib, ACALABRUTINIB , Nemtabrutinib, IBRUTINIB

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  4. VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB

    Pharma Mar S.A.

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  5. APR-246 (eprenetapopt) + Acalabrutinib in CLL

    Aprea Therapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  6. Acalabrutinib

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  8. Calquence 100 mg film-coated tablets, ACALABRUTINIB

    Cancer Prevention Pharma (Ireland) Limited

    Disseminated large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  9. Venetoclax, Venetoclax, Acalabrutinib, Venetoclax

    Ology Bioservices Ireland LTD

    Patients with relapsed CLL, Chronic lymphocytic leukemia

    phase 2 small molecule active

    1 trial

  10. A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

    Pharma Mar S.A.

    Mantle Cell Lymphoma

    phase 1 other active

    1 trial

  11. Loncastuximab Tesirine and Acalabrutinib

    ADC Therapeutics SA

    Chronic Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

  12. Acalabrutinib

    First Tracks Biotherapeutics

    Chronic Lymphocytic Leukemia

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources